- Home
- CING vs PSTV Comparison
CING vs PSTV Comparison
Compare CING & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- PSTV
- Stock Information
- Founded
- CING 2012
- PSTV 1996
- Country
- CING United States
- PSTV United States
- Employees
- CING N/A
- PSTV N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- CING Health Care
- PSTV Health Care
- Exchange
- CING Nasdaq
- PSTV Nasdaq
- Market Cap
- CING 17.3M
- PSTV 17.0M
- IPO Year
- CING 2021
- PSTV N/A
- Fundamental
- Price
- CING $5.50
- PSTV $0.53
- Analyst Decision
- CING Strong Buy
- PSTV Strong Buy
- Analyst Count
- CING 4
- PSTV 3
- Target Price
- CING $30.67
- PSTV $10.83
- AVG Volume (30 Days)
- CING 104.9K
- PSTV 19.1M
- Earning Date
- CING 08-12-2025
- PSTV 08-13-2025
- Dividend Yield
- CING N/A
- PSTV N/A
- EPS Growth
- CING N/A
- PSTV N/A
- EPS
- CING N/A
- PSTV N/A
- Revenue
- CING N/A
- PSTV $5,206,000.00
- Revenue This Year
- CING N/A
- PSTV $14.10
- Revenue Next Year
- CING N/A
- PSTV $7.96
- P/E Ratio
- CING N/A
- PSTV N/A
- Revenue Growth
- CING N/A
- PSTV N/A
- 52 Week Low
- CING $1.80
- PSTV $0.16
- 52 Week High
- CING $20.83
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- CING 66.64
- PSTV 64.56
- Support Level
- CING $4.25
- PSTV $0.27
- Resistance Level
- CING $6.01
- PSTV $0.71
- Average True Range (ATR)
- CING 0.34
- PSTV 0.05
- MACD
- CING 0.09
- PSTV 0.03
- Stochastic Oscillator
- CING 71.02
- PSTV 53.79
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).